Saturday 17 October 2026
Export VECT’s income statement to Excel — free account
VectivBio Holding AG
VECT Healthcare Biotechnology
VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
Follow VECT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 32 | 42 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.65 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 27 | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | (23) | (60) | (87) | (94) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (342.45) | |||||
| Net income | — | — | — | — | 0 | — | (23) | (60) | (87) | (94) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.62 | ||||
| Earnings | — | — | — | — | — | — | (0.69) | (6.24) | (3.23) | (2.12) | |||||
| Cash flow | — | — | — | — | — | — | (0.44) | (3.98) | (2.68) | (1.27) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (0.44) | (3.99) | (2.68) | (1.28) | |||||
| Book value | — | — | — | — | — | — | 0.27 | 3.36 | 4.30 | 4.84 | |||||
| Shares, m | — | — | — | — | — | — | 34 | 10 | 27 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 2.05 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.28) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (15) | (38) | (72) | (56) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (15) | (38) | (72) | (56) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (11) | 13 | 93 | 201 | ||||
| Total debt | — | — | — | — | — | — | 20 | 0 | 0 | 10 | |||||
| Net debt | — | — | — | — | — | — | 0 | (40) | (103) | (211) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 9 | 32 | 116 | 213 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (106.97) | (104.74) | (84.03) | (48.18) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (402.96) | (2,210.25) | |||||
| ROE | — | — | — | — | — | — | (113.16) | (288.88) | (117.39) | (56.92) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022
Charts ten years each
VectivBio Holding AG vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DBVT DBV Technologies S.A. | $572.6M | — (loss-making) | — | −53.33% (below 0%: shrinking) | n/m | −56.15% (below 0%: shrinking) | 100.00% | (7,228.57%) | Compare |
| VALN Valneva SE Sponsored ADR | $560.4M | 59.7× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| STTK Shattuck Labs, Inc. | $555.0M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VECT VectivBio Holding AG | $545.5M | — (loss-making) | — (loss-making) | — | n/m | — | 91.93% | 0.00% | |
| PBYI Puma Biotechnology, Inc. | $543.0M | 18.2× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| DRUG Bright Minds Biosciences Inc. | $534.7M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $532.3M | — (loss-making) | — | — | n/m | −174.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTMX CytomX Therapeutics, Inc. | $525.1M | — (loss-making) | — (loss-making) | −92.40% (below 0%: shrinking) | n/m | −14.50% (below 0%: shrinking) | 100.00% | (1,677.08%) | Compare |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $538.9M | — | — | −13.80% | — | −56.10% | 46.61% | 0.00% |
VectivBio Holding AG (VECT) key facts
- Concern: VectivBio Holding AG reported a net loss of $93.7 million, or a loss of $2.12 per share, for fiscal 2022.
- VectivBio Holding AG (VECT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
- Return on equity was −56.9% and debt-to-equity 0.05.
VectivBio Holding AG (VECT) Latest News
No news at this impact. Lower the threshold for more.